Back to the main directory
Company Analysis / Equity
- BMRA: Q1: Decent Revenue If Not For Disappointing Asian Sales by Zacks
- BMRA: Q2 Results: Europe Softens. IBS Advisory Board Beefed Up Further by Zacks
- BMRA: Q3 Results: Revenue Continues to Show Growth. Operational Progress on inFoods IBS Test by Zacks
- BMRA: Rebound of Asian Sales Drives 3rd Straight Qtr of Sequential Revenue Growth by Zacks
- BMRA: Look For Top-Line To Rebound in 2H 2014 by Zacks
- Asian Resurgence Taking Longer by Zacks
- Low Risk, Way Too Cheap! Initiating At Outperform by Zacks
- BVXV: Initiating Coverage of BiondVax Pharmaceuticals, Ltd.; Developing a Universal Influenza Vaccine… by Zacks
- BVXV: Phase 2b Clinical Trial of M-001 Fully Enrolled; Results Expected in Late 2016 or Early 2017 by Zacks
- BVXV: Update on First Quarter Financials; Results from Phase 2b Trial of M-001 Expected at the End of 2016… by Zacks
- CASI: Balance sheet remains strong, Stage I of Phase II of ENMD-2076 for FLC completed and advanced to stage II by Zacks
- CASI: Phase II of ENMD-2076 for FLC began to dose patients, Zevalin launched in Hong Kong--Buy by Zacks
- CASI: Stage I of Phase II of ENMD-2076 for FLC completed and advanced to stage II, Zevalin launched in Hong Kong by Zacks
- CASM: FORE-SIGHT Gobbling Up Market Share. Initiating Coverage by Zacks
- CASM: Sensors Drive 22% FORE-SIGHT Growth, 17% Total Revenue Growth by Zacks
- CBMX: Largest Study To-Date Reinforces Superiority of CMA by Zacks
- CBMX: New Record in Revenue, Margins, Test Volumes. Guiding for CF Break-Even Q4 2017 by Zacks
- CBMX: Record Testing Volumes, Reimbursement May Be Firming Up. Maintaining Buy Rec by Zacks
- CBMX: Solid Q1. Reimbursement Very Strong, Could Be At Inflection by Zacks
- CBMX: Solid Q4, PGS and Miscarriage Remain On A Tear by Zacks
- CBMX: Overhyped Risks Provide Attractive Entry Point by Zacks
- CBMX: Q4: Huge Jump in Testing Volumes, Big Beat on EPS by Zacks
- CBMX: Record Testing Volumes and Revenue by Zacks
- CBMX: Strathman Litigation Risk Now a Non-Issue by Zacks
- CEMI: $6MM Capital Raise. Maintaining Recommendation by Zacks